Cargando…

Impact of previous HIV resistance and virologic failures on virologic outcome following a switch to dolutegravir with 2 NRTIs among people living with HIV

There is uncertainty regarding the potential virologic outcome associated with a change in antiretroviral therapy (ARV) among PLHIV who had previous documented virologic failure or who have been exposure to mono/dual nucleoside reverse transcriptase inhibitors (NRTI) therapy. The objective was to me...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sangaré, Mohamed N’dongo, Baril, Jean-Guy, de Pokomandy, Alexandra, Laprise, Claudie, Deshaies, Catherine, Klein, Marina, Thomas, Réjean, Tremblay, Cécile, Roger, Michel, Pexos, Costa, Greenwald, Zoe, Machouf, Nima, Durand, Madeleine, Hardy, Isabelle, Dakouo, Mamadou, Laporte, Louise, Trottier, Helen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2020
Materias:	4850
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7676601/ https://www.ncbi.nlm.nih.gov/pubmed/33217873 http://dx.doi.org/10.1097/MD.0000000000023335

Ejemplares similares

Treatment Switch to Dolutegravir With 2 Nucleoside Reverse-Transcriptase Inhibitors (NRTI) in Comparison to Continuation With Protease Inhibitor/Ritonavir Among Patients With Human Immunodeficiency Virus at Risk for Prior NRTI Resistance: A Cohort Analysis of Real-World Data
por: Sangaré, Mohamed N’dongo, et al.
Publicado: (2020)

Removing inactive NRTIs in a salvage regimen is safe, maintains virological suppression and reduces treatment costs: 96 weeks post VERITAS study
por: Trottier, Benoit, et al.
Publicado: (2014)

Viral suppression in the era of transition to dolutegravir-based therapy in Cameroon: Children at high risk of virological failure due to the lowly transition in pediatrics
por: Fokam, Joseph, et al.
Publicado: (2023)

Discordant CSF/plasma HIV-1 RNA in individuals on virologically suppressive antiretroviral therapy in Western India
por: Dravid, Ameet N., et al.
Publicado: (2018)

Soluble PD-L1: a potential immune marker for HIV-1 infection and virological failure
por: Avendaño-Ortiz, José, et al.
Publicado: (2020)

Elevated CD8 T-cell counts and virological failure in HIV-infected patients after combination antiretroviral therapy
por: Ku, Nam Su, et al.
Publicado: (2016)

Efavirenz versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: A prospective study of HIV-positive individuals
por: Cain, Lauren E., et al.
Publicado: (2016)

Tolerability and effectiveness of albuvirtide combined with dolutegravir for hospitalized people living with HIV/AIDS
por: Liu, Huanxia, et al.
Publicado: (2023)

Adherence to Antiretroviral Therapy and Virologic Failure: A Meta-Analysis
por: Bezabhe, Woldesellassie M., et al.
Publicado: (2016)

Nevirapine plasma concentration is associated with virologic failure and the emergence of drug-resistant mutations among HIV patients in Kenya: A cross sectional study
por: Omondi, Evans Okumu, et al.
Publicado: (2022)

Epicardial fat density, coronary artery disease and inflammation in people living with HIV
por: Sadouni, Manel, et al.
Publicado: (2023)

Two case reports of severe myocarditis associated with the initiation of dolutegravir treatment in HIV patients
por: Mahlab-Guri, Keren, et al.
Publicado: (2016)

Factors associated with immunological and virological discordant responses to highly active antiretroviral therapy among adult HIV positive individuals in Ethiopia: A cross-sectional study
por: Manaye, Gizachew Ayele, et al.
Publicado: (2021)

HIV-1 subtype diversity, drug resistance, and genetic transmission networks in men who have sex with men with virologic failure in antiretroviral therapy in Sichuan, China, 2011 to 2017
por: Yuan, Dan, et al.
Publicado: (2019)

Case report of Triumeq (abacavir/dolutegravir/lamivudine) associated rhabdomyolysis in a human immunodeficiency virus (HIV) infected patient
por: Saad, Muhammad, et al.
Publicado: (2019)

Long-term effectiveness of unboosted atazanavir plus abacavir/lamivudine in subjects with virological suppression: A prospective cohort study
por: Llibre, Josep M., et al.
Publicado: (2016)

Real-world efficacy and safety of dolutegravir plus lamivudine versus tenofovir plus lamivudine and efavirenz in ART-naïve HIV-1-infected adults
por: Li, Jin, et al.
Publicado: (2022)

Should viral load thresholds be lowered?: Revisiting the WHO definition for virologic failure in patients on antiretroviral therapy in resource-limited settings
por: Labhardt, Niklaus D., et al.
Publicado: (2016)

Cross-sectional study of virological failure and multinucleoside reverse transcriptase inhibitor resistance at 12 months of antiretroviral therapy in Western India
por: Karade, Santosh K., et al.
Publicado: (2016)

Effect of Dolutegravir regimen against other regimens on some hematological parameters, CD4 count and viral load of people living with HIV infection in South Eastern Nigeria
por: Echefu, Stella N., et al.
Publicado: (2023)

Lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients
por: Maggiolo, Franco, et al.
Publicado: (2017)

High levels of virological failure with major genotypic resistance mutations in HIV-1-infected children after 5 years of care according to WHO-recommended 1st-line and 2nd-line antiretroviral regimens in the Central African Republic: A cross-sectional study
por: Mossoro-Kpinde, Christian Diamant, et al.
Publicado: (2017)

Dolutegravir plus rilpivirine: benefits beyond viral suppression: DORIPEX retrospective study
por: Troya, Jesús, et al.
Publicado: (2022)

Dolutegravir: Virologic response and tolerability of initial antiretroviral regimens for adults living with HIV
por: Correa, Analú, et al.
Publicado: (2020)

Virological Failure in HIV to Triple Therapy With Dolutegravir-Based Firstline Treatment: Rare but Possible
por: Pena, M J, et al.
Publicado: (2018)

Predictors of virological failure in HIV‐1‐infected patients switching to dolutegravir maintenance monotherapy
por: Wijting, IEA, et al.
Publicado: (2018)

Real life use of dolutegravir doravirine dual regimen in experienced elderly PLWH with multiple comorbidities and on polypharmacy: A retrospective analysis
por: Mazzitelli, Maria, et al.
Publicado: (2021)

Long-term outcome of lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients
por: Maggiolo, Franco, et al.
Publicado: (2022)

HIV and cancer registry linkage identifies a substantial burden of cancers in persons with HIV in India
por: Godbole, Sheela V., et al.
Publicado: (2016)

Second-Line HIV Therapy Outcomes and Determinants of Mortality at the Largest HIV Referral Center in Southern Vietnam
por: Thao, Vu Phuong, et al.
Publicado: (2015)

Hospitalizations of HIV patients in a major Israeli HIV/AIDS center during the years 2000 to 2012
por: Mahlab-Guri, Keren, et al.
Publicado: (2017)

Oral microbiome in HIV-associated periodontitis
por: Noguera-Julian, Marc, et al.
Publicado: (2017)

Reproductive history before and after HIV diagnosis: A cross-sectional study in HIV-positive women in Spain
por: Hernando, Victoria, et al.
Publicado: (2017)

Detection and genotyping of human papillomavirus (HPV) in HIV-infected women and its relationship with HPV/HIV co-infection
por: Badial, Rodolfo Miglioli, et al.
Publicado: (2018)

HIV incidence and behavioral correlates of HIV acquisition in a cohort of injection drug users in St Petersburg, Russia
por: Kozlov, Andrei P., et al.
Publicado: (2016)

HIV viral exposure and mortality in a multicenter ambulatory HIV adult cohort, United States, 1995–2016
por: Palella, Frank J., et al.
Publicado: (2021)

Self-reported motivators for HIV testing in the treat-all era among HIV positive patients in Johannesburg, South Africa
por: Mokhele, Idah, et al.
Publicado: (2021)

Sociodemographic differences among HIV-positive and HIV-negative recently pregnant women in Mexico City: A case–control study
por: Aguilar-Zapata, Daniel, et al.
Publicado: (2017)

Metabolic syndrome and 10-year cardiovascular risk among HIV-positive and HIV-negative adults: A cross-sectional study
por: Masyuko, Sarah J., et al.
Publicado: (2020)

Hepatic fibrosis and immune phenotype vary by HCV viremia in HCV/HIV co-infected subjects: A Women's interagency HIV study
por: Desai, Seema N., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_v0lsl4hv8mr8s4eeur82om28m8